Advertisement

European Journal of Clinical Pharmacology

, Volume 72, Issue 5, pp 513–521 | Cite as

Prevalence of statin-drug interactions in older people: a systematic review

  • Michele Thai
  • Emily Reeve
  • Sarah N Hilmer
  • Katie Qi
  • Sallie-Anne Pearson
  • Danijela Gnjidic
Review

Abstract

Purpose

Statins are among the most frequently prescribed medications internationally. Older people are commonly prescribed multiple medications and are at an increased risk of drug-drug interactions, including statin-drug interactions. The aim of this study was to conduct a systematic review of current evidence on the prevalence of statin-drug interactions in older people.

Methods

A systematic search of observational studies in Embase, Medline, and PubMed was conducted. Articles were included if they were published in English during the period July 2000–July 2014 and reported on the prevalence of statin-drug interactions in people over 65 years of age. Two reviewers independently assessed the articles for eligibility and extracted the data.

Results

The search returned 1556 eligible articles. A total of 19 articles met the inclusion criteria. In studies (n = 7) that focused on statin users only, the prevalence of potential statin-drug interactions assessed using different measures ranged from 0.19 to 33.0 %. In studies that examined drug interactions across a population of both statin users and non-users (n = 12), the prevalence of potential statin-drug interactions ranged from 0.1 to 7.1 % (n = 8), and the prevalence of clinically relevant statin-drug interactions ranged from 1.5 to 4 % (n = 4).

Conclusions

Current published evidence suggests substantial variations in the prevalence of statin-drug interactions and their clinical relevance. Further studies are necessary to provide a better understanding of the prevalence of clinically significant statin-drug interactions, the medications most frequently contributing to statin-drug interactions, and impact on relevant clinical outcomes in older people.

Keywords

Statins Drug-drug interactions Older people Prevalence 

Notes

Acknowledgments

Danijela Gnjidic is supported by a National Health and Medical Research Early Career Fellowship. Sallie-Anne Pearson is a Cancer Institute NSW Career Development Fellow. Emily Reeve is employed by the NHMRC Cognitive Decline Partnership Centre which receives financial support from the Australian National Health and Medical Research Council and partners Alzheimer’s Australia and aged care providers HammondCare, HelpingHand, and Brightwater.

Author contributions

All authors contributed to conception and planning of the article. MT, ER, KQ, and DG contributed to manuscript acquisition, analysis, and interpretation of the data. All authors contributed to paper drafting, critical revision, and have approved the final version of the manuscript.

References

  1. 1.
    Morgan TK, Williamson M, Pirotta M, Stewart K, Myers SP, Barnes J (2012) A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust 196:50–53CrossRefPubMedGoogle Scholar
  2. 2.
    Elliott RA (2006) Problems with medication use in the elderly: an Australian perspective. J Pharm Pract 36:58–66CrossRefGoogle Scholar
  3. 3.
    Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C (2013) Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother 47:324–332CrossRefPubMedGoogle Scholar
  4. 4.
    Johnell K, Klarin I (2007) The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 30:911–918CrossRefPubMedGoogle Scholar
  5. 5.
    Gnjidic D, Johnell K (2013) Clinical implications from drug-drug and drug-disease interactions in older people. Clin Exp Pharmacol Physiol 40:320–325CrossRefPubMedGoogle Scholar
  6. 6.
    Hilmer SN, McLachlan AJ, Le Couteur DG (2007) Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 21:217–230CrossRefPubMedGoogle Scholar
  7. 7.
    Hines LE, Murphy JE (2011) Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother 9:364–377CrossRefPubMedGoogle Scholar
  8. 8.
    Wallach Kildemoes H, Vass M, Hendriksen C, Andersen M (2012) Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour. Health Policy 108:216–227CrossRefPubMedGoogle Scholar
  9. 9.
    Lo-Ciganic WH, Boudreau RM, Gray SL et al (2013) Changes in cholesterol-lowering medications use over a decade in community-dwelling older adults. Ann Pharmacother 47:984–992CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gnjidic D, Le Couteur DG, Blyth FM et al (2013) Statin use and clinical outcomes in older men: a prospective population-based study. BMJ Open 3(3):e002333CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ (2008) Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol 51:37–45CrossRefPubMedGoogle Scholar
  12. 12.
    Roberts CG, Guallar E, Rodriguez A (2007) Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci 62:879–887CrossRefPubMedGoogle Scholar
  13. 13.
    Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278CrossRefPubMedGoogle Scholar
  14. 14.
    Bellosta S, Corsini A (2012) Statin drug interactions and related adverse reactions. Expert Opin Drug Saf 11:933–946CrossRefPubMedGoogle Scholar
  15. 15.
    Ho CKM, Walker SW (2011) Statins and their interactions with other lipid-modifying medications: safety issues in the elderly. Ther Adv Drug Saf 3:35–46CrossRefGoogle Scholar
  16. 16.
    Bottorff MB (2006) Statin safety and drug interactions: clinical implications. Am J Cardiol 97:27C–31CCrossRefPubMedGoogle Scholar
  17. 17.
    Corsini A, Ceska R (2011) Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? Curr Med Res Opin 27:1551–1562CrossRefPubMedGoogle Scholar
  18. 18.
    Cabrera MA, Dip RM, Furlan MO, Rodrigues SL (2009) Use of drugs that act on the cytochrome P450 system in the elderly. Clinics (Sao Paulo, Brazil) 64:273–278CrossRefGoogle Scholar
  19. 19.
    Bakhai A, Rigney U, Hollis S, Emmas C (2012) Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf 21:485–493CrossRefPubMedGoogle Scholar
  20. 20.
    Ming EE, Davidson MH, Gandhi SK et al (2008) Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol 2:453–463CrossRefPubMedGoogle Scholar
  21. 21.
    Piacentini N, Trifiro G, Tari M, Moretti S, Arcoraci V, group U (2005) Statin-macrolide interaction risk: a population-based study throughout a general practice database. Eur J Clin Pharmacol 61:615–620CrossRefPubMedGoogle Scholar
  22. 22.
    Einarson TR, Metge CJ, Iskedjian M, Mukherjee J (2002) An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme a reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther 24:2126–2136CrossRefPubMedGoogle Scholar
  23. 23.
    Egger SS, Ratz Bravo AE, Hess L, Schlienger RG, Krahenbuhl S (2007) Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 24:429–440CrossRefPubMedGoogle Scholar
  24. 24.
    Karimi S, Hough A, Beckey C, Parra D (2010) Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center. J Manag Care Pharm 16:472–481PubMedGoogle Scholar
  25. 25.
    Petropoulos JB, Bello-Quintero CE (2004) Frequency of simvastatin prescriptions with potentially interacting medications in a Veterans Affairs health care system. J Manag Care Pharm 10:239–243PubMedGoogle Scholar
  26. 26.
    Bacic-Vrca V, Marusic S, Erdeljic V, Falamic S, Gojo-Tomic N, Rahelic D (2010) The incidence of potential drug-drug interactions in elderly patients with arterial hypertension. Pharm World Sci 32:815–821CrossRefPubMedGoogle Scholar
  27. 27.
    Ghibelli S, Marengoni A, Djade CD et al (2013) Prevention of inappropriate prescribing in hospitalized older patients using a computerized prescription support system (intercheck registered trademark). Drugs Aging 30:821–828CrossRefPubMedGoogle Scholar
  28. 28.
    Halvorsen KH, Granas AG, Engeland A, Ruths S (2012) Prescribing quality for older people in Norwegian nursing homes and home nursing services using multidose dispensed drugs. Pharmacoepidemiol Drug Saf 21:929–936CrossRefPubMedGoogle Scholar
  29. 29.
    Kerr KP, Mate KE, Magin PJ et al (2014) The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians. J Clin Pharm Ther 39:383–389CrossRefPubMedGoogle Scholar
  30. 30.
    Lao CK, Ho SC, Chan KK, Tou CF, Tong HHY, Chan A (2013) Potentially inappropriate prescribing and drug-drug interactions among elderly Chinese nursing home residents in Macao. Int J Clin Pharm 35:805–812CrossRefPubMedGoogle Scholar
  31. 31.
    Lea M, Rognan SE, Koristovic R, Wyller TB, Molden E (2013) Severity and management of drug-drug interactions in acute geriatric patients. Drugs Aging 30:721–727CrossRefPubMedGoogle Scholar
  32. 32.
    Marcum ZA, Driessen J, Thorpe CT, Gellad WF, Donohue JM (2014) Effect of multiple pharmacy use on medication adherence and drug-drug interactions in older adults with medicare part D. J Am Geriatr Soc 62:244–252CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Pasina L, Djade CD, Nobili A et al (2013) Drug-drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiol Drug Saf 22:1054–1060PubMedGoogle Scholar
  34. 34.
    Popovic B, Quadranti NR, Matanovic SM et al (2014) Potentially inappropriate prescribing in elderly outpatients in Croatia. Eur J Clin Pharmacol 70:737–744CrossRefPubMedGoogle Scholar
  35. 35.
    Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST (2008) Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300:2867–2878CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Roughead EE, Kalisch LM, Barratt JD, Gilbert AL (2010) Prevalence of potentially hazardous drug interactions amongst Australian veterans. Br J Clin Pharmacol 70:252–257CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Dudash K, Negri G, Baccarini S, Rabinowitz C, Maio V (2011) Prevalence and predictors of potentially significant drug-drug interactions in the elderly. Value Health 14:A7CrossRefGoogle Scholar
  38. 38.
    Espinosa-Bosch M, Santos-Ramos B, Gil-Navarro MV, Santos-Rubio MD, Marin-Gil R, Villacorta-Linaza P (2012) Prevalence of drug interactions in hospital healthcare. Int J Clin Pharm 34:807–817CrossRefPubMedGoogle Scholar
  39. 39.
    Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH (2007) Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 16:641–651CrossRefPubMedGoogle Scholar
  40. 40.
    Hassan FA, Taylor DM, Leow FHP, Doolan G, Knott JC (2006) Potential interactions between drugs taken by emergency department patients of an Australian hospital. J Pharm Pract 36:266–270CrossRefGoogle Scholar
  41. 41.
    Florentin M, Elisaf MS (2012) Simvastatin interactions with other drugs. Expert Opin Drug Saf 11:439–444CrossRefPubMedGoogle Scholar
  42. 42.
    Neuvonen PJ, Niemi M, Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565–581CrossRefPubMedGoogle Scholar
  43. 43.
    Ronaldson KJ, O'Shea JM, Boyd IW (2006) Risk factors for rhabdomyolysis with simvastatin and atorvastatin. Drug Saf 29:1061–1067CrossRefPubMedGoogle Scholar
  44. 44.
    Vitry AI (2007) Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 63:709–714CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Vonbach P, Dubied A, Krahenbuhl S, Beer JH (2008) Evaluation of frequently used drug interaction screening programs. Pharm World Sci 30:367–374CrossRefPubMedGoogle Scholar
  46. 46.
    Saito M, Hirata-Koizumi M, Urano T, Miyake S, Hasegawa R (2005) A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J Clin Pharm Ther 30:21–37CrossRefPubMedGoogle Scholar
  47. 47.
    Thai M, Hilmer S, Pearson SA, Reeve E, Gnjidic D (2015) Prevalence of potential and clinically relevant statin-drug interactions in frail and robust older inpatients. Drugs Aging 32:849–856CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Michele Thai
    • 1
  • Emily Reeve
    • 2
    • 3
    • 5
  • Sarah N Hilmer
    • 2
    • 3
  • Katie Qi
    • 1
  • Sallie-Anne Pearson
    • 1
    • 4
    • 5
  • Danijela Gnjidic
    • 1
    • 2
  1. 1.Faculty of PharmacyThe University of SydneySydneyAustralia
  2. 2.Sydney Medical SchoolThe University of SydneySydneyAustralia
  3. 3.Kolling Institute of Medical ResearchRoyal North Shore HospitalSt LeonardsAustralia
  4. 4.School of Public HealthThe University of SydneySydneyAustralia
  5. 5.Centre for Big Data Research in HealthUNSW AustraliaSydneyAustralia

Personalised recommendations